Clinical Trials Logo

Clinical Trial Summary

uterine NK (uNK) cells are characterized by a high expression of CD56 (CD56brihgt), lack of CD16 expression, high secretion of cytokines and rather low cytotoxic activity. It has been shown that uNK cells increase in number during the late secretory phase and during early pregnancy. This study was designed to assess the possible role of uNK cells in repeated ICSI failure.


Clinical Trial Description

For occurrence of the "window of implantation", the endometrium must proliferate, increase in thickness, then, after ovulation, adequately respond to progesterone, and become receptive. Ultrasound examination of the thickness and appearance of the endometrium is an easily performed means of assessing morphological changes occurring in the endometrium during the follicular phase, and is thus used as a measure to predict successful implantation. Indeed, several studies have reported a strong association between endometrial thickness and successful implantation. However, others failed to confirm such an association. The minimal adequate endometrial thickness for successful implantation, as measured in the late proliferative phase, varies between studies, with a range of 6-8 mm. However, although rare, some investigators have reported successful implantation in an endometrium of no more than 5 mm thickness. Uterine NK cell testing can only be done via an endometrial biopsy. Uterine natural killer cells never come into direct contact with the fetal cells-they only have direct access to placental cells.The biopsy is performed on day 21 of your menstrual cycle, when the NK cell count is at its highest. The procedure is done at outpatient clinics and results take about two weeks to receive. If your NK cell activity reading is greater than 14 % on day 21 biopsy, then diagnosed with high levels of NK cell activity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04867759
Study type Observational
Source Tanta University
Contact Ayman Dawoog, MD
Phone +202020972067
Email [email protected]
Status Not yet recruiting
Phase
Start date May 1, 2021
Completion date September 1, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01933893 - Follicular Versus Luteal Pipelle in Repeated Implantation Failure Patients N/A
Recruiting NCT04497558 - The Clinical Efficiency of Tb-ERA in Chinese RIF Patients N/A
Completed NCT01493440 - Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure N/A
Not yet recruiting NCT02967419 - The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure N/A
Not yet recruiting NCT02893722 - A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment Phase 1
Recruiting NCT03405883 - Uterine Microbiome in Women With Repeated Implantation Failure and Normal Fertile Women N/A
Completed NCT03445910 - Intrauterine Injection of Human Chorionic Gonadotrophin and Pregnancy Rate in ICSI N/A
Recruiting NCT04698109 - Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gynecological Diseases
Recruiting NCT04533295 - The Effect of Acupuncture on IVF Pregnancy Outcomes for Women With RIF N/A